A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania

被引:14
|
作者
Perrin, E.
Anand, E. [1 ]
Dyachkova, Y.
Wagner, T. [2 ]
Frediani, S. [3 ]
Ballerini, A. [4 ]
机构
[1] Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
[2] Lilly Deutschland GmbH, D-61350 Bad Homburg, Germany
[3] Psychiat Dept Venice, Natl Mental Hlth Serv, Venice, Italy
[4] Santa Maria Nuova Hosp, Serv Psichiatr Diagnosi & Cura, Florence, Italy
关键词
Agitation; Schizophrenia; Bipolar mania; IM psychotropic drugs; Acute dystonia; Akathisia; Parkinsonism; OLANZAPINE; MANAGEMENT; ANTIPSYCHOTICS; EFFICACY;
D O I
10.1016/j.eurpsy.2010.04.005
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This naturalistic, observational pan-European study assessed the safety and early effectiveness of intramuscular (IM) psychotropic treatments in patients with acute agitation suffering from schizophrenia or bipolar mania. One thousand nine hundred and forty of 1945 patients completed the 24-hour observation period after initial IM treatment. Patients from 12 European countries were included (mean age 39 years; 58% male, 66% schizophrenia). IM treatment was at the physician's discretion. The primary objective was to describe the acute tolerability of IM psychotropic therapies in clinical practice, with particular emphasis on EPS. At baseline, 68% of the patients received IM monotherapy, with IM olanzapine most commonly prescribed (36%). During the first 24 hours, 190 (9.8%) patients experienced EPS. The occurrence of EPS was statistically significantly lower in patients treated with IM olanzapine compared to those treated with other IM psychotropic medications (mainly typical antipsychotics and benzodiazepines): acute dystonia: 1.1%, 95% CI 0.5-2.3 and 2.9%, CI 2.0-4.0; akathisia: 2.3%, CI 1.3-3.7 and 5.5%, CI 4.3-6.9; Parkinsonism: 2.9%, CI 1.8-4.4 and 7.8%, CI 6.4-9.4, respectively. Anticholinergic treatment was given to 12% IM olanzapine versus 31% non-olanzapine treated patients. Acute agitation after 24 hours was reduced by 1.68 (95% CI 1.46-1.91) points on the Clinical Global Impression of Severity (CGI-S) in IM olanzapine patients and 1.51 (95% CI 1.30-1.73) points in non-olanzapine patients. Additional psychotropic medication was required for 90% of the patients during the first 24 hours of treatment. Results provide naturalistic evidence for low EPS rates and improvement of agitation with IM psychotropic medications during acute states of patients suffering from acute mania or schizophrenia. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 50 条
  • [41] Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
    Nasrallah, Henry A.
    Silva, Robert
    Phillips, Debra
    Cucchiaro, Josephine
    Hsu, Jay
    Xu, Jane
    Loebel, Antony
    JOURNAL OF PSYCHIATRIC RESEARCH, 2013, 47 (05) : 670 - 677
  • [42] The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
    Wu, Yaxue
    Li, Yanli
    Liang, Weiye
    Bai, Luyuan
    Yu, Jianjin
    Li, Keqing
    Zhang, Yunshu
    Guo, Yanmei
    Liu, Zenglong
    Wang, Jian
    Zhang, Congpei
    Wang, Xijin
    Xu, Jia
    Liu, Liping
    Li, Juan
    Yang, Fude
    BMC PSYCHIATRY, 2023, 23 (01)
  • [43] The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
    Yaxue Wu
    Yanli Li
    Weiye Liang
    Luyuan Bai
    Jianjin Yu
    Keqing Li
    Yunshu Zhang
    Yanmei Guo
    Zenglong Liu
    Jian Wang
    Congpei Zhang
    Xijin Wang
    Jia Xu
    Liping Liu
    Juan Li
    Fude Yang
    BMC Psychiatry, 23
  • [44] A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
    Rappaport, Stephen A.
    Marcus, Ronald N.
    Manos, George
    McQuade, Robert D.
    Oren, Dan A.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2009, 10 (01) : 21 - 27
  • [45] Cognitive behavioural treatment of negative symptoms in schizophrenia patients: study design of the TONES study, feasibility and safety of treatment
    Klingberg, Stefan
    Wittorf, Andreas
    Herrlich, Jutta
    Wiedemann, Georg
    Meisner, Christoph
    Buchkremer, Gerhard
    Frommann, Nicole
    Woelwer, Wolfgang
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2009, 259 : 149 - 154
  • [46] An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis
    Horga, Alejandro
    Castillo, Joaquin
    Rio, Jordi
    Tintore, Mar
    Auger, Cristina
    Sastre-Garriga, Jaume
    Carmen Edo, M.
    Perez-Miralles, Francisco
    Tur, Carmen
    Nos, Carlos
    Huerga, Elena
    Comabella, Manuel
    Rovira, Alex
    Montalban, Xavier
    REVISTA DE NEUROLOGIA, 2011, 52 (06) : 321 - 330
  • [47] Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea
    Rhee, Yumie
    Chang, Dong-Gune
    Ha, Jeonghoon
    Kim, Sooa
    Lee, Yusun
    Jo, Euna
    Koh, Jung-Min
    ENDOCRINOLOGY AND METABOLISM, 2022, 37 (03) : 497 - 505
  • [48] Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Takai, Kentaro
    Higuchi, Teruhiko
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2683 - 2695
  • [49] Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia
    Kelebie, Mulualem
    Kibralew, Getasew
    Tadesse, Gebresilassie
    Rtbey, Gidey
    Aderaw, Mekidem
    Endeshaw, Wondale
    Belachew, Mitiku
    Muche, Mulu
    Getnet, Diemesew
    Fentahun, Setegn
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [50] A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia
    Malhotra, Nidhi
    Kulhara, Parmanand
    Chakrabarti, Subho
    Grover, Sandeep
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 150 (02) : 653 - 658